News

AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSilk4Care

Neuried, Germany, 10 June 2025 – AMSilk, a global leader in…

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

Industry and scientific experts in molecular biology, immunology…

Amber Implants Announces Successful One-Year Follow-Up Data in First-in-Human Clinical of VCFix® Spinal System

One-year follow-up data from first-in-human trial shows significant…

iOnctura bolsters leadership team with new appointments

Steven Sciuto joins as Chief Financial Officer (CFO) bringing…

Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply Partnership

Strategic agreement secures access to essential oncology injectables…

Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer

Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’…

Poolbeg Pharma plc – Poolbeg granted FDA Orphan Drug Designation for POLB 001

27 May 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Poolbeg Pharma plc – Annual Report, AGM Notice & Circular

27 May 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the…

Poolbeg Pharma plc – Proposed Retail Offer to raise up to £100,000

Poolbeg Pharma plc (AIM: POLB, 'Poolbeg Pharma' or the 'Company'),…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.